Tuba Hilkay KARAPINAR, Ersin DURGUN, Yeşim OYMAK, Nesrin GÜLEZ, Yılmaz AY, Ferah GENEL, Salih GÖZMEN, Sultan AYDIN KÖKER, Erkin SERDAROĞLU, Ersin TORET, Canan VERGİN
Children with chronic-refractory autoimmune cytopenias: a single center experience
Background and objectives. Autoimmune cytopenias are a group of heterogeneous disorders characterized by immune-mediated destruction of one or more hematopoietic lineage cells. The differential diagnosis of children with autoimmune cytopenias requires much time and laboratory investigations. The aim of the present study was to evaluate the clinical course and significance of autoimmune cytopenias due to immunodeficiency or autoimmune diseases in children at a single children’s hospital. Method. Between February 1997 and September 2015, chronic/refractory autoimmune cytopenias patient data were evaluated retrospectively. Twenty-three patients were assessed in this study. Results. The median duration of following was 2.6 years (4 months-18.5 years). The median age of diagnosis was 3.1 years (6 months-16 years). A total of 13 patients (56.5%) had single-lineage and 10 (46.5%) had multilineage cytopenias. The most frequent single-lineage cytopenia was thrombocytopenia, followed by anemia. In 22 of the patients, cytopenias was detected before the primary diseases. All of the patients were treated with corticosteroids or intravenous immune globulin as first-line treatment. Ten patients (43.5%) needed second or further-line immunosuppressive therapies that patients diagnosed as systemic lupus erythematosus, hypogammaglobulinemia, or common variable immunodeficiency. A total of 8 patients (34.7%) recovered from autoimmune cytopenias after the treatment of primer disease. Cytopenias were continued in 14 patients. Conclusion. Cytopenia may be the first finding of an immunodeficiency or autoimmune disease and primary disease may be diagnosed in the clinical course. Taking the new targeted treatment options into consideration; early diagnosis is likely to become more important in the near-future in order to begin the treatment for the underlying disease as early as possible.
___
1. Miano M, Scalzone M, Perri K, et al. Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: a single centre experience. Br J Haematol 2015; 171: 247-253.2. Price V. Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood. Pediatr Blood Cancer 2013; 60(Suppl 1): S12-S14.
3. Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood 2014; 124: 2337-2344.
4. Teachey DT, Lambert MP. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr Clin North Am 2013; 60: 1489- 1511.
5. Al Ghaithi I, Wright NA, Breakey VR, et al. Combined autoimmune cytopenias presenting in childhood. Pediatr Blood Cancer 2016; 63: 292-298.
6. Aladjidi N, Leverger G, Leblanc T, et al; Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE). New insights into childhood autoimmune hemolytic anemia: a French National Observational Study of 265 children. Haematologica 2011; 96: 655-663.
7. Bride KL, Vincent T, Smith-Whitley K, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 2016; 127: 17-28.
8. Ghosh S, Seidel MG. Editorial: Current challenges in immune and other acquired cytopenias of childhood. Front Pediatr 2016; 4: 3.
9. Rao VK. Approaches to managing autoimmune cytopenias in novel immunological disorders with genetic underpinnings like autoimmune lymphoproliferative syndrome. Front Pediatr 2015; 3: 65.
10. Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005; 25: 57-62.
11. Aladjidi N, Fernandes H, Leblanc T, et al. Evans syndrome in children: long-term outcome in a Prospective French National Observational Cohort. Front Pediatr 2015; 3: 79.
12. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207.
13. Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Nelson Textbook of Pediatrics. (18th ed). Philadelphia: Saunders Elsevier, 2007.
14. Dale DC, Bolyard AA, Schwinzer BG, et al. The severe chronic neutropenia International Registry: 10-year follow-up report. Support Cancer Ther 2006; 3: 220-231.
15. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145: 709- 727.
16. Bousfiha AA, Jeddane L, Ailal F, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol 2013; 33: 1078-1087.
17. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 2010; 116: e35-e40.
18. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686.
19. Sipurzynski J, Fahrner B, Kerbl R, et al. Management of chronic immune thrombocytopenia in children and adolescents: lessons from an Austrian national cross-sectional study of 81 patients. Semin Hematol 2016; 53(Suppl 1): S43-S47.
20. Savaşan S, Warrier I, Buck S, Kaplan J, Ravindranath Y. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans' syndrome. Clin Immunol (Orlando, Fla) 2007; 125: 224-229.
21. Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev 2002; 16: 61-64.
22. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010; 116: 7-15.
23. Resnick ES, Moshier El, Godbold JH, CunninghamRundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119: 1650-1657.
24. Warnatz K, Voll RE. Pathogenesis of autoimmunity in common variable immunodeficiency. Front Immunol 2012; 3: 210.
25. Neven B, Magerus-Chatinet A, Florkin B, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 2011; 118: 4798-4807.
26. Lube GE, Ferriani MPL, Campos LMA, et al. Evans syndrome at childhood-onset systemic lupus erythematosus diagnosis: a large multicenter study. Pediatr Blood Cancer 2016; 63: 1238-1243.
27. Podjasek JC, Abraham RS. Autoimmune cytopenias in common variable immunodeficiency. Front Immunol 2012; 3: 189.
28. Sankaran J, Rodriguez V, Jacob EK, Kreuter JD, Go RS. Autoimmune hemolytic anemia in children: Mayo Clinic Experience. J Pediatr Hematol Oncol 2016; 38: e120-e124.
29. Wang WC. Evans syndrome in childhood: pathophysiology, clinical course, and treatment. Am J Pediatr Hematol Oncol 1988; 10: 330-338.
30. Hammarström L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol 2000; 120: 225-231.
31. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011; 20: 1345-1355.
32. Miescher PA, Tucci A, Beris P, Favre H. Autoimmune hemolytic anemia and/or thrombocytopenia associated with lupus parameters. Semin Hematol 1992; 29: 13-17.
33. Iqbal S, Sher MR, Good RA, Cawkwell GD. Diversity in presenting manifestations of systemic lupus erythematosus in children. J Pediatr 1999; 135: 500- 505.
34. Schmugge M, Revel-Vilk S, Hiraki L, Rand ML, Blanchette VS, Silverman ED. Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. J Pediatr 2003; 143: 666-669.
35. Shcherbina A, Rosen FS, Remold-O'Donnell E. Pathological events in platelets of Wiskott-Aldrich syndrome patients. Br J Haematol 1999; 10: 875-883.
36. Marathe BM, Prislovsky A, Astrakhan A, Rawlings DJ, Wan JY, Strom TS. Antiplatelet antibodies in WASP(-) mice correlate with evidence of increased in vivo platelet consumption. Exp Hematol 2009; 37: 1353-1363.
- ISSN: 0041-4301
- Yayın Aralığı: Yılda 6 Sayı
- Başlangıç: 1958
- Yayıncı: Hacettepe Üniversitesi Çocuk Sağlığı Enstitüsü Müdürlüğü
Sayıdaki Diğer Makaleler
Quanyao CHEN, Zhiyi HUANG, Yao CHEN
Orhan TUNÇ, Burhanettin GÖNÜLDAŞ, İsmail AYTAÇ, Semih MUMBUÇ, Muzaffer KANLIKAMA
Diverse clinical characteristics of Aspergillus growth in patients with cystic fibrosis
Nagehan EMİRALİOĞLU, DENİZ DOĞRU ERSÖZ, Özlem AKGÜN DOĞAN, Dolunay GÜLMEZ, SEVTAP ARIKAN AKDAĞLI, Sanem ERYILMAZ POLAT, Gökçen Dilşa TUĞCU, Mina HIZAL, Ebru YALÇIN, Uğur ÖZÇELİK, Burçin ŞENER, Nural KİPER
Pacemaker lead-induced tricuspid stenosis treated with percutaneous valvotomy
Nilüfer ÇETİNER, Işık Yıldırım BAŞTUHAN, Tolga ÖZYİĞİT, Alpay ÇELİKER
Sema AYLAN GELEN, Nazan SARPER, Emine ZENGİN
A rare cause of secondary hemophagocytic lymphohistiocytosis: systemic loxoscelism
Tuğba ERAT, Aysun YAHŞİ, Cem ÇANAKÇI, Aybike KORKMAZ, Ceyda KARAHAN, Talia İLERİ, Savaş SEREL, Huban ATİLLA, Nihal KUNDAKÇI, Halil ÖZDEMİR, Erdal İNCE, Ergin ÇİFTÇİ
Özlem BOYBEYİ TÜRER, TUTKU SOYER, Erkan PARLAK, Hatice NURSUN ÖZCAN, Cenk Yücel BİLEN, Feridun C. TANYEL
Xanthogranulomatous pyelonephritis due to calculi in a 5-year-old girl
Esra Nagehan AKYOL ÖNDER, Mine ÖZKOL, Nalan NEŞE, Can TANELİ, İpek ÖZÜNAN
Different clinical presentation in a patient with two novel pathogenic variants of the FBXL4 gene
Engin KÖSE, Melis KÖSE, Zeynep AKIŞIN, Selvinaz EDİZER, Ferah GENEL, Zehra Burcu YILMAZ, Ahmet ŞAHİN